The Prescription Pattern and Side-effect Profile of Bupropion
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective：Bupropion use has recently increased in Korea because of its unique mechanism of action and favorable side-effect profile. In this cross-sectional survey, we examined the prescription pattern and side-effect profile of bupropion in psychiatric practice. Methods：A total of 107 psychiatrists participated in this survey conducted from April 2007 to September 2007. The survey included questions on the drug combinations used, the clinical diagnosis, clinical global impression, side effects, and the age and sex of patients. The data from 1085 cases were analyzed. Results：The mean age of the patients was 43.4±17.1 years (range, 6−80 years), and 629 (58.0%) were women and 441 (40.6%) were men. Bupropion was most commonly prescribed for depressive disorder (85.6%), but was also used to treat anxiety disorder (7.0%), somatoform disorder (1.9%), attention-deficit hyperactivity disorder (1.6%), psychotic disorder (1.3%), and adjustment disorder (1.1%). Bupropion monotherapy was used in 51% of the patients, and bupropion was used in combination with other antidepressants in 49% of the patients. In most (96.6%) of the combination therapy cases, bupropion was used with one antidepressant. Diagnosis and the severity of symptoms determined whether bupropion was used alone or in combination therapy and the side-effect profile of the two therapies differed slightly. The overall frequency of side effects was 11.9% in bupropion monotherapy, and the most common were insomnia, nausea/vomiting, anxiety, and loss of appetite. Conclusions：Bupropion was prescribed most often for patients with depressive disorders, but the data indicated that it is increasingly used for other psychiatric disorders. Bupropion was found to have a favorable side-effect profile.
Abstract
Objective：Bupropion use has recently increased in Korea because of its unique mechanism of action and favorable side-effect profile. In this cross-sectional survey, we examined the prescription pattern and side-effect profile of bupropion in psychiatric practice. Methods：A total of 107 psychiatrists participated in this survey conducted from April 2007 to September 2007. The survey included questions on the drug combinations used, the clinical diagnosis, clinical global impression, side effects, and the age and sex of patients. The data from 1085 cases were analyzed. Results：The mean age of the patients was 43.4±17.1 years (range, 6−80 years), and 629 (58.0%) were women and 441 (40.6%) were men. Bupropion was most commonly prescribed for depressive disorder (85.6%), but was also used to treat anxiety disorder (7.0%), somatoform disorder (1.9%), attention-deficit hyperactivity disorder (1.6%), psychotic disorder (1.3%), and adjustment disorder (1.1%). Bupropion monotherapy was used in 51% of the patients, and bupropion was used in combination with other antidepressants in 49% of the patients. In most (96.6%) of the combination therapy cases, bupropion was used with one antidepressant. Diagnosis and the severity of symptoms determined whether bupropion was used alone or in combination therapy and the side-effect profile of the two therapies differed slightly. The overall frequency of side effects was 11.9% in bupropion monotherapy, and the most common were insomnia, nausea/vomiting, anxiety, and loss of appetite. Conclusions：Bupropion was prescribed most often for patients with depressive disorders, but the data indicated that it is increasingly used for other psychiatric disorders. Bupropion was found to have a favorable side-effect profile.
참고문헌 (30)
- Stahl SM, "A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor", Prim Care Companion J Clin Psychiatry, 6, pp.159~166 (2004)
- Foley KF, "Bupropion: pharmacology and therapeutic applications", Expert Rev Neurother, 6, pp.1249~1265 (2006)
- Thase ME, "harmacotherapy of bipolar depression: an update", Curr Psychiatry Rep, 8, pp.478~488 (2006)
- Meszaros A, "Pharmacotherapy of adult attention deficit", hyperactivity disorder (ADHD): a systematic review, 2007, pp.22, 259~270
- Wilkes S, "The use of bupropion SR in cigarette smoking cessation", Int J Chron Obstruct Pulmon Dis, 3, pp.45~53 (2008)
- Cullum JL, "Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients", Can J Psychiatry, 49, pp.139~144 (2004)
- Rush AJ, "Depression, IV: STAR*D treatment trial for depression", Am J Psychiatry, 160, pp.237~ (2003)
- Zisook S, "Use of bupropion in combination with serotonin reuptake inhibitors", Biol Psychiatry, 59, pp.203~210 (2006)
- Leuchter AF, "An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder", J Psychiatr Pract, 14, pp.271~280 (2008)
- Clark NA, "Increased rate of trazodone prescribing with bupropion and selective serotonin-reuptake inhibitors versus tricyclic antidepressants", Ann Pharmacother, 34, pp.1007~1012 (2000)
- Kirsch MA, "Combination treatment with venlafaxine and bupropion", Am J Psychiatry, 156, pp.494~ (1999)
- Demyttenaere K, "Review: Bupropion and SSRIinduced side effects", J Psychopharmacol, 22, pp.792~804 (2008)
- 박원명, "장기 유지 치료에서 새로운 항우울제의 내약성：Bupropion SR(Wellbutrin SR)을 중심으로", 대한정신약물학회지, 16(1), pp.16~24 (2005), 대한정신약물학회
- Zimmerman M, "Why isn't bupropion the most frequently prescribed antidepressant?", J Clin Psychiatry, 66, pp.603~610 (2005)
- Mercerolle M, "A fatal case of bupropion (Zyban) overdose", J Anal Toxicol, 32, pp.192~196 (2008)
- Association AP, "Diagnostic and statistical manual of mental disorders. 4th ed. text revision" (2000), American psychiatric Association
- Guy W, "ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publication No. ADM 76−338). Superintendent of Documents" (1976), Government Printing Office
- Association AP, "Practice guideline for the treatment of patients with bipolar disorder (revision)", Am J Psychiatry, 159, pp.1~50 (2002)
- Suppes T, "The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder", J Clin Psychiatry, 66, pp.870~886 (2005)
- Post RM, "Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline", Br J Psychiatry, 189, pp.124~131 (2006)
- Sheehan DV, "Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias", J Clin Psychopharmacol, 3, pp.28~31 (1983)
- Gebhardt S, "Treatment of panic disorder with bupropion in a patient with Parkinson's disease", J Clin Pharm Ther, 33, pp.575~577 (2008)
- Simon NM, "Bupropion sustained release for panic disorder", Psychopharmacol Bull, 37, pp.66~72 (2003)
- Spencer TJ, "Novel treatments for attention-deficit", hyperactivity disorder in children, 2002, pp.63, 16~22
- Semenchuk MR, "Efficacy of sustained-release bupropion in neuropathic pain: an open-label study", n J Pain, 16, pp.6~11 (2000)
- Bailey J, "Acute psychosis after bupropion treatment in a healthy 28-year-old woman", J Am Board Fam Med, 21, pp.244~245 (2008)
- Mischoulon D, "Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians", Can J Psychiatry, 45, pp.476~481 (2000)
- Perlis RH, "Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice", Harv Rev Psychiatry, 10, pp.109~114 (2002)
- Rojo JE, "Combined antidepressants: clinical experience", Acta Psychiatr Scand Suppl, 428, pp.25~31 (2005)
- Pesola GR, "Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department", J Emerg Med, 22, pp.235~239 (2002)